ישראל - עברית - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - ethinylestradiol; gestodene - טבליות מצופות פילם - ethinylestradiol 0.015 mg; gestodene 0.06 mg - gestodene and estrogen - gestodene and estrogen - contraceptive.

ישראל - עברית - Ministry of Health

rekah pharmaceutical industry ltd, israel - dexamethasone - טבליה - dexamethasone 2 mg - dexamethasone - dexamethasone - anti - inflammatory.

ישראל - עברית - Ministry of Health

rekah pharmaceutical industry ltd, israel - dexamethasone - טבליה - dexamethasone 0.5 mg - dexamethasone - dexamethasone - anti-inflammatory.

ישראל - עברית - Ministry of Health

rekah pharmaceutical industry ltd, israel - hydrocortisone - טבליה - hydrocortisone 10 mg - hydrocortisone - hydrocortisone - anti inflammatory.

ישראל - עברית - Ministry of Health

neurim pharmaceuticals (1991) ltd, israel - melatonin - טבליות בשחרור ממושך - melatonin 1 mg - melatonin

ישראל - עברית - Ministry of Health

neurim pharmaceuticals (1991) ltd, israel - melatonin - טבליות בשחרור ממושך - melatonin 5 mg - melatonin

ישראל - עברית - Ministry of Health

merck sharp & dohme israel ltd - ezetimibe 10 mg; simvastatin 10 mg - tablets - simvastatin - hypercholesterolemia: inegy is indicated as adjunctive therapy to diet for use in patients with primary ( heterozygous familial and nonfamilial) hypercholesterolemia or mixed hyperlipidemia where use of a combination product is appropriate: - patients not appropriately controlled with a statin alone - patients already treated with a statin and ezetimibe. inegy contains ezetimibe and simvastatin. simvastatin ( 20 - 40 mg ) has been shown to reduce the frequency of cardiovascular events. studies to demonstrate the efficacy of inegy or ezetimibe in the prevention of complications of atherosclerosis have not been completed. homozygous familial hypercholesterolemia (hofh): inegy is indicated as adjunctive therapy to diet for use in patients with hofh.patients may also receive adjunctive treatments ( e.g. low-density lipoprotein [ldl] apheresis).

ישראל - עברית - Ministry of Health

merck sharp & dohme israel ltd - ezetimibe; simvastatin - טבליה - simvastatin 20 mg; ezetimibe 10 mg - simvastatin - simvastatin - hypercholesterolemia: inegy is indicated as adjunctive therapy to diet for use in patients with primary ( heterozygous familial and nonfamilial) hypercholesterolemia or mixed hyperlipidemia where use of a combination product is appropriate: - patients not appropriately controlled with a statin alone - patients already treated with a statin and ezetimibe. inegy contains ezetimibe and simvastatin. simvastatin ( 20 - 40 mg ) has been shown to reduce the frequency of cardiovascular events. studies to demonstrate the efficacy of inegy or ezetimibe in the prevention of complications of atherosclerosis have not been completed. homozygous familial hypercholesterolemia (hofh): inegy is indicated as adjunctive therapy to diet for use in patients with hofh.patients may also receive adjunctive treatments ( e.g. low-density lipoprotein [ldl] apheresis).

ישראל - עברית - Ministry of Health

merck sharp & dohme israel ltd - ezetimibe; simvastatin - טבליה - ezetimibe 10 mg; simvastatin 20 mg - simvastatin - simvastatin - hypercholesterolemia: inegy is indicated as adjunctive therapy to diet for use in patients with primary ( heterozygous familial and nonfamilial) hypercholesterolemia or mixed hyperlipidemia where use of a combination product is appropriate: - patients not appropriately controlled with a statin alone - patients already treated with a statin and ezetimibe. inegy contains ezetimibe and simvastatin. simvastatin ( 20 - 40 mg ) has been shown to reduce the frequency of cardiovascular events. studies to demonstrate the efficacy of inegy or ezetimibe in the prevention of complications of atherosclerosis have not been completed. homozygous familial hypercholesterolemia (hofh): inegy is indicated as adjunctive therapy to diet for use in patients with hofh. patients may also receive adjunctive treatments ( e.g. low-density lipoprotein [ldl] apheresis).

ישראל - עברית - Ministry of Health

merck sharp & dohme israel ltd - ezetimibe; simvastatin - טבליה - simvastatin 40 mg; ezetimibe 10 mg - simvastatin - simvastatin - hypercholesterolemia: inegy is indicated as adjunctive therapy to diet for use in patients with primary ( heterozygous familial and nonfamilial) hypercholesterolemia or mixed hyperlipidemia where use of a combination product is appropriate: - patients not appropriately controlled with a statin alone - patients already treated with a statin and ezetimibe. inegy contains ezetimibe and simvastatin. simvastatin ( 20 - 40 mg ) has been shown to reduce the frequency of cardiovascular events. studies to demonstrate the efficacy of inegy or ezetimibe in the prevention of complications of atherosclerosis have not been completed. homozygous familial hypercholesterolemia (hofh): inegy is indicated as adjunctive therapy to diet for use in patients with hofh. patients may also receive adjunctive treatments ( e.g. low-density lipoprotein [ldl] apheresis).